JPMPG Review of the Defense Health Board Recommendations Regarding Pandemic Influenza Preparedness and Response

Informational Brief

Lt Col Philip L. Gould
Chair
Joint Preventive Medicine Policy Group
Recommendations

The DHB recommendations on pandemic influenza preparedness and response were released on **11 Sep 2009**, and covered 6 topic areas:

- 1. Antivirals
- 2. Lab diagnostics
- 3. Surveillance
- 4. Research
- 5. Vaccine issues
- 6. Communications / Coordination
Antivirals

• DoD is following both FDA and CDC (ACIP) recommendations. (Recs a & b)
• Current DoD stockpiling follows national and international (WHO) recommendations (Recs c & d)
• Supplemental funding for antivirals and PPE has been achieved. Expanded antiviral availability with addition of Relenza and amantadine to local and strategic stockpiles. (Recs)
Lab Diagnostics

• 2 DoD laboratories (NHRC & USAFSAM) were the first in the world to identify the novel H1N1 influenza. (Rec f comment)

• NHRC has expanded lab testing capacity by 3-5x (>15000); USAFSAM by 6-8x (>24000), nearly all sites with some DoD personnel have submitted specimens to one or both labs. (Rec h)

• Additionally 3 Army MEDCENs and 2 NEPMUs are now online providing testing (7 MEDCENs will be able to turn on once FDA approved assay available)
Lab Diagnostics (2)

• Testing algorithm has been in place before these recommendations (Rec i)
  – Sample only patients with ILI (fever of >38 C with cough or sore throat). Max 6-10 specimens per week per site
  – Favor hospitalized pts, antiviral resistant, and case clusters larger than 5 patients in high risk groups (e.g. deployed or trainees)

• USAFSAM has been at near 100% of samples sequenced for the hemagglutinin gene (Rec i)

• JBAIDs has been under EUA since August; validated at 5 CENTCOM sites by USAFSAM & NAMRU-3 since Sep (Rec j)
Surveillance

• Expanded number of countries in which there is influenza surveillance of host nationals (Rec f)
• DoD is actively involved in hospitalization surveillance, and provides info to CDC (Rec f)
• MILVAX, AFHSC, the FDA's Center for Biologics Evaluation and Research, and the CDC's Immunization Safety Office are coordinating safety surveillance on the new H1N1 vaccine (Rec q)
Research

• The Military Infectious Diseases Research Program held a meeting Sep 09 to evaluate need for a respiratory diseases research program (Rec k)

• The DoD has a long standing involvement in respiratory disease clinical research and epidemiology, including partnering with other agencies, e.g. CDC partner in cross-neutralizing antibody research (Recs e, l, o).

• NHRC and NMRC are actively involved in vaccine clinical trials (e.g. adenovirus 4/7; H1N1 DNA based vaccine) (Rec l)
Research (2)

• Some research is not military-unique and may be better accomplished in the civilian sector or as a collaboration (e.g. multidrug antiviral therapy) (Rec c)

• NMRC has funded a clinical trial in convalescent plasma therapy. Collaborating with NIH, USUHS, FDA, other Services to set up trial network (Rec m)
Vaccines

- DoD was involved in the initial decision-making. Plan was changed by POTUS (Recs p & s)
  - Original plan had allocations for DoD at each step, incl coverage for Guard/Reserve.
- Decision to use the vaccine was also national policy (Rec r)
- Draft policy on use of pneumococcal vaccine (23-valent polysaccharide) in review at ASD(HA) (Rec n)
Communications/Coordination

• DoD has coordinated with other agencies in surveillance, research, vaccine distribution, and communications (Recs g, l, t)

• The DoD watchboard, Pentagon homepage, MILVAX website, as well as DoD-sponsored Twitter and Facebook sites have provided:
  – Vaccine availability and locations
  – 2009 H1N1 influenza clinical and prevention information
Questions

• Contact info:
  – Philip.gould@pentagon.af.mil
  – Comm: 703-588-6470
  – DSN 425-6470
BACKUP SLIDES
Defense Health Board (DHB)

• The Defense Health Board is a Federal Advisory Committee to the Secretary of Defense providing independent scientific advice and recommendations on health and healthcare research, operations, and delivery.

• The recommendations were developed from the Infectious Diseases Subcommittee of the DHB
Vaccine Safety

• MILVAX and the interagency team has evaluated over 800K Service members who have received the Novel A(H1N1) vaccine.

• There continues to be no increase in safety concerns compared to previous seasonal influenza vaccine campaigns.

• DoD is following 12 cases that may be associated with the vaccine: 4 thrombocytopenia, 6 bells palsy, 1 guillian-barre syndrome, 1 transverse myelitis. Note: these do not represent an increase compared to background, but are being followed for completeness.
Acronym List

• ACIP Advisory Committee on Immunization Practices
• AFHSC Armed Forces Health Surveillance Center
• ASD (HA) Assistant Secretary of Defense Health Affairs
• CDC Centers for Disease Control and Prevention
• CENTCOM U.S. Central Command
• DHB Defense Health Board
• DNA Deoxyribonucleic Acid
• DoD Department of Defense
• EUA Emergency Use Authorization
• FDA Food and Drug Administration
• ILI Influenza Like Illness
• JBAIDS Joint Biological Agent Identification and Diagnostic System
• JPMPG Joint Preventive Medicine Policy Group
Acronym List (2)

- MEDCEN U.S. Army Medical Center
- MILVAX Military Vaccine Office
- NAMRU-3 Naval Medical Research Unit, No. 3 (Cairo, Egypt)
- NEPMU Navy Environmental and Preventive Medicine Unit
- NHRC Naval Health Research Center
- NIH National Institutes of Health
- NMRC Naval Medical Research Center
- POTUS President of the United States
- USAFSAM U.S. Air Force School of Aerospace Medicine
- USUHS Uniformed Services University of the Health Sciences
- WHO World Health Organization